vs
Side-by-side financial comparison of ADC Therapeutics SA (ADCT) and Entrada Therapeutics, Inc. (TRDA). Click either name above to swap in a different company.
ADC Therapeutics SA is the larger business by last-quarter revenue ($23.1M vs $20.6M, roughly 1.1× Entrada Therapeutics, Inc.). On growth, ADC Therapeutics SA posted the faster year-over-year revenue change (36.4% vs -65.2%). Over the past eight quarters, ADC Therapeutics SA's revenue compounded faster (13.7% CAGR vs 6.4%).
ADC Telecommunications, Inc. was a communications company in Eden Prairie, Minnesota, a southwest suburb of Minneapolis. It was acquired by TE Connectivity in December 2010 and ceased to exist as a separate entity. ADC products were sold by CommScope after it acquired the Broadband Network Solutions business unit from TE Connectivity in August 2015.
Entrada Therapeutics is a clinical-stage biotechnology firm developing transformative intracellular therapies for serious rare diseases and high-unmet-need disorders. Its pipeline covers neuromuscular, metabolic, and central nervous system segments, serving global patients via healthcare partnerships.
ADCT vs TRDA — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $23.1M | $20.6M |
| Net Profit | — | $-17.3M |
| Gross Margin | — | — |
| Operating Margin | -77.7% | -106.0% |
| Net Margin | — | -84.4% |
| Revenue YoY | 36.4% | -65.2% |
| Net Profit YoY | — | -173.8% |
| EPS (diluted) | $0.04 | $-0.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $23.1M | — | ||
| Q3 25 | $15.8M | — | ||
| Q2 25 | $18.1M | — | ||
| Q1 25 | $17.4M | $20.6M | ||
| Q4 24 | $16.9M | $37.4M | ||
| Q3 24 | $18.0M | $19.6M | ||
| Q2 24 | $17.0M | $94.7M | ||
| Q1 24 | $17.8M | $59.1M |
| Q4 25 | — | — | ||
| Q3 25 | $-41.0M | — | ||
| Q2 25 | $-56.6M | — | ||
| Q1 25 | $-38.6M | $-17.3M | ||
| Q4 24 | — | $1.1M | ||
| Q3 24 | $-44.0M | $-14.0M | ||
| Q2 24 | $-36.5M | $55.0M | ||
| Q1 24 | $-46.6M | $23.5M |
| Q4 25 | -77.7% | — | ||
| Q3 25 | -196.6% | — | ||
| Q2 25 | -244.1% | — | ||
| Q1 25 | -163.5% | -106.0% | ||
| Q4 24 | -191.8% | -15.7% | ||
| Q3 24 | -197.4% | -110.7% | ||
| Q2 24 | -170.5% | 56.4% | ||
| Q1 24 | -188.3% | 35.7% |
| Q4 25 | — | — | ||
| Q3 25 | -260.1% | — | ||
| Q2 25 | -313.2% | — | ||
| Q1 25 | -221.8% | -84.4% | ||
| Q4 24 | — | 3.0% | ||
| Q3 24 | -244.1% | -71.7% | ||
| Q2 24 | -214.6% | 58.1% | ||
| Q1 24 | -261.1% | 39.7% |
| Q4 25 | $0.04 | — | ||
| Q3 25 | $-0.30 | — | ||
| Q2 25 | $-0.50 | — | ||
| Q1 25 | $-0.36 | $-0.42 | ||
| Q4 24 | $-0.26 | $-0.20 | ||
| Q3 24 | $-0.42 | $-0.35 | ||
| Q2 24 | $-0.38 | $1.55 | ||
| Q1 24 | $-0.56 | $0.68 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $261.3M | $67.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-185.8M | $417.3M |
| Total Assets | $323.1M | $486.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $261.3M | — | ||
| Q3 25 | $234.7M | — | ||
| Q2 25 | $264.6M | — | ||
| Q1 25 | $194.7M | $67.8M | ||
| Q4 24 | $250.9M | $101.2M | ||
| Q3 24 | $274.3M | $78.0M | ||
| Q2 24 | $300.1M | $185.3M | ||
| Q1 24 | $234.3M | $68.4M |
| Q4 25 | $-185.8M | — | ||
| Q3 25 | $-238.2M | — | ||
| Q2 25 | $-199.2M | — | ||
| Q1 25 | $-238.2M | $417.3M | ||
| Q4 24 | $-202.6M | $428.7M | ||
| Q3 24 | $-171.9M | $422.4M | ||
| Q2 24 | $-131.7M | $429.9M | ||
| Q1 24 | $-194.4M | $269.4M |
| Q4 25 | $323.1M | — | ||
| Q3 25 | $289.8M | — | ||
| Q2 25 | $321.6M | — | ||
| Q1 25 | $272.5M | $486.5M | ||
| Q4 24 | $322.0M | $526.3M | ||
| Q3 24 | $349.1M | $554.6M | ||
| Q2 24 | $371.8M | $582.0M | ||
| Q1 24 | $308.0M | $510.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-31.1M | $-38.5M |
| Free Cash FlowOCF − Capex | — | $-39.7M |
| FCF MarginFCF / Revenue | — | -192.9% |
| Capex IntensityCapex / Revenue | 0.0% | 5.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-58.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-31.1M | — | ||
| Q3 25 | $-29.6M | — | ||
| Q2 25 | $-24.1M | — | ||
| Q1 25 | $-56.3M | $-38.5M | ||
| Q4 24 | $-21.9M | $-31.6M | ||
| Q3 24 | $-25.0M | $-24.3M | ||
| Q2 24 | $-32.8M | $39.8M | ||
| Q1 24 | $-44.1M | $-25.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $-56.6M | $-39.7M | ||
| Q4 24 | $-21.9M | $-32.2M | ||
| Q3 24 | $-25.3M | $-24.9M | ||
| Q2 24 | $-32.9M | $38.8M | ||
| Q1 24 | $-44.6M | $-26.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -325.2% | -192.9% | ||
| Q4 24 | -129.8% | -86.2% | ||
| Q3 24 | -140.2% | -127.3% | ||
| Q2 24 | -193.0% | 41.0% | ||
| Q1 24 | -250.0% | -44.6% |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 1.5% | 5.6% | ||
| Q4 24 | 0.5% | 1.7% | ||
| Q3 24 | 1.2% | 3.3% | ||
| Q2 24 | 0.2% | 1.1% | ||
| Q1 24 | 3.0% | 1.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -27.94× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.72× | ||
| Q1 24 | — | -1.09× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
